PT-141 — the research name for bremelanotide — is a synthetic cyclic heptapeptide that acts as an agonist at the melanocortin receptors, most notably MC4R. It is a close structural relative of Melanotan II and one of the most thoroughly characterized melanocortin agonists in the published literature, studied in both receptor-binding work and human clinical trials. This article covers what PT-141 is at the molecular level, where it came from, how it engages the central melanocortin system, what published research has measured, and how it relates to its parent compound.
What PT-141 is at the molecular level
PT-141 is a cyclic heptapeptide — a seven-residue backbone closed into a ring by a lactam bridge rather than left as a free linear chain. The cyclization is not incidental: the bridge locks the molecule into a fixed conformation, the feature pharmacology studies associate with its potency and durability at melanocortin receptors relative to the short-lived native hormone it descends from.
Functionally it is a melanocortin receptor agonist — a ligand that binds and activates members of that receptor family. Molinoff et al. (Ann N Y Acad Sci, 2003) described it as a synthetic analog of α-melanocyte-stimulating hormone (α-MSH) engaging receptors expressed predominantly in the central nervous system, with its activity at MC3R and MC4R as the basis of its pharmacological profile.
Origin: derived from Melanotan II and α-MSH
PT-141 sits at the end of a well-documented design lineage that begins with α-MSH, the 13-residue endogenous melanocortin peptide, and runs through Melanotan II — itself a cyclic, truncated, lactam-bridged analog of α-MSH. PT-141 is the deaminated metabolite of Melanotan II: structurally it corresponds to Melanotan II with the C-terminal amide replaced by a free carboxylic acid, so the two share essentially the same ring scaffold and differ at a single terminal position.
That close kinship is why the two are so frequently discussed together. For a structural comparison of the broader Melanotan family — linear versus cyclic backbones and receptor selectivity — see our companion article on Melanotan 1 vs Melanotan 2. In short, PT-141 inherits the constrained cyclic heptapeptide chassis of Melanotan II, with the C-terminal modification distinguishing it as its own characterized molecule.
Melanocortin-receptor mechanism: a central, MC4R-led profile
The defining feature of PT-141 in the literature is that it is studied as a centrally acting melanocortin agonist. The melanocortin receptors are a family of five G-protein-coupled receptors, MC1R through MC5R. Of these, MC3R and MC4R are concentrated in the brain — particularly in hypothalamic and limbic regions — and MC4R is the receptor most associated with PT-141’s central pharmacology in published work (Molinoff et al., Ann N Y Acad Sci, 2003).
This central, receptor-mediated mechanism is what investigators contrast with the peripheral action of PDE5 inhibitors such as sildenafil, which act downstream in vascular tissue by inhibiting phosphodiesterase type 5 to alter local blood flow. PT-141 instead operates centrally, engaging brain melanocortin receptors — so the literature treats the two as mechanistically distinct classes: central melanocortin signaling versus peripheral vascular enzyme inhibition.
What published research and trials measured
PT-141 / bremelanotide has been evaluated across early-phase pharmacology studies and large randomized clinical trials. The following summarizes what the cited studies measured in their research populations — not outcomes attributed to any reader.
- Receptor and pharmacology characterization. Molinoff et al. characterized PT-141 as a synthetic melanocortin agonist whose engagement of centrally expressed MC3R and MC4R forms the basis of its activity, distinguishing it from peripherally acting agents (Molinoff et al., Ann N Y Acad Sci, 2003).
- Intranasal pharmacokinetics and pharmacodynamics. A double-blind, placebo-controlled study gave intranasal PT-141 to healthy male volunteers and participants with mild-to-moderate erectile dysfunction, measuring safety, plasma pharmacokinetics, and RigiScan-recorded erectile response (Diamond et al., Int J Impot Res, 2004).
- Subcutaneous administration in Viagra non-responders. Rosen et al. evaluated subcutaneous PT-141 in healthy male subjects and in patients reporting an inadequate response to Viagra, again using RigiScan to quantify the erectile response alongside safety and pharmacokinetic measures (Rosen et al., Int J Impot Res, 2004).
- Phase 3 trials in female research subjects (RECONNECT). Two identical randomized, double-blind, placebo-controlled Phase 3 trials studied subcutaneous bremelanotide in premenopausal women clinically diagnosed with hypoactive sexual desire disorder, with co-primary endpoints of change from baseline on the Female Sexual Function Index desire domain and a Female Sexual Distress Scale item (Kingsberg et al., Obstet Gynecol, 2019).
- Long-term safety follow-up. A subsequent open-label extension measured long-term safety and tolerability in the same population, reporting the most common treatment-emergent adverse events as tolerability-related and predominantly mild to moderate (Simon et al., Obstet Gynecol, 2019).
Across these studies, bremelanotide is the melanocortin agonist that progressed furthest in clinical research — the compound studied clinically for hypoactive sexual desire disorder in premenopausal women, the indication the RECONNECT program was designed around.
How PT-141 relates to Melanotan II
The cleanest way to situate PT-141 is as the deaminated, carboxyl-terminal form of Melanotan II: the same lactam-bridged ring, differing only where Melanotan II carries a C-terminal amide and PT-141 a free acid. That single change defines PT-141 as a distinct research compound, while the shared scaffold explains why both are broad melanocortin agonists engaging MC4R among other subtypes. Melanotan II is most often discussed in pigmentation-related melanocortin research; PT-141 is the analog whose published record centers on central MC3R/MC4R pharmacology and the human trials summarized above.
Frequently asked questions
What is PT-141?
PT-141 is the research name for bremelanotide, a synthetic cyclic heptapeptide that acts as a melanocortin receptor agonist. In the published literature it is characterized chiefly through its activity at the centrally expressed MC3R and MC4R subtypes (Molinoff et al., 2003).
Is PT-141 the same as bremelanotide?
Yes. “PT-141” and “bremelanotide” refer to the same molecule. PT-141 is the original research designation; bremelanotide is the assigned nonproprietary name used in the later clinical trial literature.
How is PT-141 related to Melanotan II?
PT-141 is the deaminated metabolite of Melanotan II. The two share the same cyclic, lactam-bridged heptapeptide scaffold derived from α-MSH and differ at the C-terminus, where Melanotan II has an amide and PT-141 has a free carboxylic acid.
Which melanocortin receptor is PT-141 associated with?
Its central pharmacology is most associated with MC4R, with MC3R also implicated — the subtypes concentrated in hypothalamic and limbic regions of the brain (Molinoff et al., 2003).
How does PT-141’s mechanism differ from a PDE5 inhibitor?
The literature describes PT-141 as a centrally acting melanocortin agonist that engages brain receptors, whereas PDE5 inhibitors such as sildenafil act peripherally by inhibiting phosphodiesterase type 5 in vascular tissue — two mechanistically distinct classes.
What did the clinical trials of bremelanotide measure?
The Phase 3 RECONNECT program measured change from baseline on validated questionnaire endpoints — the Female Sexual Function Index desire domain and a Female Sexual Distress Scale item — in premenopausal women clinically diagnosed with hypoactive sexual desire disorder (Kingsberg et al., 2019), and a follow-up study measured long-term safety in the same population (Simon et al., 2019).
References
- Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003. PMID: 12851303.
- Diamond LE, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004. PMID: 14963471.
- Rosen RC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004. PMID: 14999221.
- Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019. PMID: 31599840.
- Simon JA, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019. PMID: 31599847.
For research use only. The products and materials discussed are intended for laboratory research purposes and are not for human or veterinary use, diagnosis, or treatment. This article describes the chemical structure and published pharmacological research of a compound and does not constitute a claim of any effect in any individual.
